Dave Grayzel

Dave S.
Grayzel was the founder of Ataxion, Inc. founded in 2013, serving as Chief Executive Officer & Director.
Dr. Grayzel was the founder of Annovation BioPharma, Inc. founded in 2011, serving as Chief Executive Officer from 2011 to 2015.
Dr. Grayzel was the founder of Arteaus Therapeutics LLC founded in 2011, serving as Chief Executive Officer from 2011 to 2014.
Dr. Grayzel was the founder of Surface Oncology, Inc. founded in 2014, serving as Chairman from 2015 to 2017.
Dr. Grayzel is the founder of Acera School founded in 2009, serving as Director since 2009.
Dr. Grayzel is the founder of Q32 Bio, Inc. founded in 2024, serving as Independent Director since 2024.
Dr. Grayzel was also the founder of Cadent Therapeutics, Inc...
Current positions included Director at Q32 Bio Operations, Inc. since 2020; Independent Director at Affinia Therapeutics, Inc. since 2020; Director at TRIANA Biomedicines, Inc.; Director at Comanche Biopharma Corp.; Director at Radera Biotherapeutics, Inc.; Director at Vima Therapeutics, Inc.; Partner at Atlas Venture Advisors, Inc. since 2014; Advisor at Memorial Sloan Kettering Cancer Center; Partner at Atlas Venture Life Science Advisors LLC since 2014; Member at Tri-Institutional Therapeutics Discovery Institute, Inc.; Member at One Brave Idea, Inc. Former positions include Director of Corporate Development at Dyax Corp.
from 2000 to 2002; Curriculum Director at Stanford Health Care-Stanford Hospital; Director at Xilio Therapeutics, Inc. from 2018 to 2021; Director at Delinia, Inc. from 2015 to 2017; Independent Director at Jade Biosciences, Inc. from 2020 to 2025; VP-Clinical Development & Medical Affairs at Infinity Pharmaceuticals, Inc. from 2002 to 2010; Principal at Quartet Medicine, Inc. Education includes undergraduate degree from Stanford University and doctorate from Harvard Medical School conferred in 1997.